MedKoo product information:

 Mitomycin C

mitomycin C is a methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

MUTAMYCIN® (mitomycin for injection, USP) (also known as mitomycin and/or mitomycin-C) is an antibiotic isolated from the broth of Streptomyces caespitosus which has been shown to have antitumor activity. The compound is heat stable, has a high melting point, and is freely soluble in organic solvents.

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity. It is given intravenously to treat upper gastro-intestinal (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin c 0.02% is applied topically for 20 seconds to prevent haze after PRK or superlasik. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. (the information was directly from http://en.wikipedia.org/wiki/Mitomycin_C).

CLINICAL PHARMACOLOGY

MUTAMYCIN selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of MUTAMYCIN-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. In humans, MUTAMYCIN is rapidly cleared from the serum after intravenous administration. Time required to reduce the serum concentration by 50% after a 30 mg bolus injection is 17 minutes. After injection of 30 mg, 20 mg, or 10 mg I.V., the maximal serum concentrations were 2.4 µg/mL, 1.7 µg/mL, and 0.52 µg/mL, respectively. Clearance is effected primarily by metabolism in the liver, but metabolism occurs in other tissues as well. The rate of clearance is inversely proportional to the maximal serum concentration because, it is thought, of saturation of the degradative pathways. Approximately 10% of a dose of MUTAMYCIN is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases with increasing dose. In children, excretion of intravenously administered MUTAMYCIN is similar.

 1: Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1133-40. Epub 2008 Jun 27. PubMed PMID: 18584240.

2: Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT. Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie. 2008 May;31(5):271-81. Epub 2008 Apr 10. Review. PubMed PMID: 18497518.

3: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

4: Lu W, Li YH, Yu ZJ, He XF, Chen Y, Zhao JB, Zhu ZY. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology. 2007 Jul-Aug;54(77):1499-502. PubMed PMID: 17708284.

5: Nishioka M, Miyamoto H, Kurita N, Higashijima J, Yoshikawa K, Miyatani T, Shimada M. Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. Hepatogastroenterology. 2007 Jun;54(76):1089-93. PubMed PMID: 17629045.

6: Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. In Vivo. 2006 Nov-Dec;20(6A):715-8. PubMed PMID: 17203752.

7: Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. Review. PubMed PMID: 17103105.

8: Le Page S, Kwiatkowski F, Paulin C, Mohamed F, Pezet D, Chipponi J, Benhamed M, Gilly FN, Glehen O. In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C. Hepatogastroenterology. 2006 Sep-Oct;53(71):693-7. PubMed PMID: 17086870.

9: Lu YF, Zeng J, Liao QH, Lin J, Huang Y, Chen JQ, Tian L, Xie NC. [Comparative study on clinical effect of postoperative arterial infusion chemotherapy and systemic chemotherapy in gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Jul;9(4):317-9. Chinese. PubMed PMID: 16886113.

10: Hao SH, Liu FL. [Chemoembolization of bilateral internal iliac arteries in Miles operation]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Jun;31(3):353-4, 407. Chinese. PubMed PMID: 16859122.

11: Watanabe M, Kodaira S, Takahashi T, Tominaga T, Hojo K, Kato T, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M. Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil. Langenbecks Arch Surg. 2006 Aug;391(4):330-7. Epub 2006 Jun 21. PubMed PMID: 16823593.

12: Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006 Jan;7(1):43-51. PubMed PMID: 16389183.

13: Shakuto S, Noguchi K, Bissery MC. [Antitumor effect of docetaxel against human endometrial tumor cell lines]. Gan To Kagaku Ryoho. 2005 Oct;32(10):1437-42. Japanese. PubMed PMID: 16227744.

14: Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y. Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol. 2005 Nov-Dec;28(6):736-43. PubMed PMID: 16132387.

15: Mizuno K, Kidokoro K, Miyazaki K, Yoshida K, Nakagawa A, Mizuno M, Suzuki S, Kuno N, Furuhashi M, Ishizuka T, Ishikawa K. [Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer]. Gan To Kagaku Ryoho. 2005 Jun;32(6):815-9. Japanese. PubMed PMID: 15984522.

16: Fiorentini G, Rossi S, Bonechi F, Vaira M, De Simone M, Dentico P, Bernardeschi P, Cantore M, Guadagni S. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004 Jun;16(3):293-7. PubMed PMID: 15330328.

17: Danson S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev. 2004 Aug;30(5):437-49. Review. PubMed PMID: 15245776.

18: Yuan S, Zhang X, Lu L, Xu C, Yang W, Ding J. Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs. 2004 Jul;15(6):641-6. PubMed PMID: 15205610.

19: Favoulet P, Benoit L, Osmak L, Polycarpe E, Esquis P, Duvillard C, Guiu B, Rat P, Favre JP, Chauffert B. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice. World J Surg. 2004 May;28(5):451-6. Epub 2004 Apr 19. PubMed PMID: 15085402.

20: Lu W, Li Y, He X, Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology. 2003 Nov-Dec;50(54):2079-83. PubMed PMID: 14696468.

21: Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5. Review. PubMed PMID: 12577232.

22: Lu W, Li YH, He XF, Chen Y, Zeng QL, Qiu YR. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma. Di Yi Jun Yi Da Xue Xue Bao. 2002 Jun;22(6):524-6. PubMed PMID: 12297475.

23: Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 2002;62(14):2089-126. Review. PubMed PMID: 12269857.

24: Villalona-Calero MA, Kolesar JM. Mitomycin as a modulator of irinotecan anticancer activity. Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):21-5. PubMed PMID: 12199629.

25: Grosios K. MitoExtra SuperGen. Curr Opin Investig Drugs. 2002 Apr;3(4):648-51. PubMed PMID: 12090738.

26: Girling DJ, Muers MF, Qian W, Lobban D. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin Oncol. 2002 Feb;29(1):97-101. Review. PubMed PMID: 11836674.

27: Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, Guo YP, Lin XJ, Li GH. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol. 2002 Feb;8(1):74-8. PubMed PMID: 11833075.

28: Seitz JF, Duffaud F, Dahan L, Ries P, Ville E, Laugier R. [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?]. Cancer Radiother. 2001 Nov;5 Suppl 1:107s-112s. French. PubMed PMID: 11797269.

29: Kim R, Yoshida K, Toge T. [Current status and future perspectives on chemotherapy in patients with gastric cancer: can the clinical data from Japan lead to a standard international therapy?]. Nippon Geka Gakkai Zasshi. 2001 Oct;102(10):770-7. Review. Japanese. PubMed PMID: 11681004.

30: Utsunomiya T, Emi Y, Ikejiri K, Suzuki M, Saitsu H, Yakabe S, Nonaka M, Saku M, Yoshida K, Shimada M, Sugimachi K. Retrospective study on the effects of lipiodolization before a potentially curative hepatectomy for colorectal liver metastases: long-term results of a pilot study. Hepatogastroenterology. 2001 May-Jun;48(39):790-3. PubMed PMID: 11462925.

31: Eurvilaichit C, Chuapetcharasopon C. Hepatic arterial collaterals after transcatheter oily chemoembolization of hepatocellular carcinoma. J Med Assoc Thai. 2001 Jan;84(1):75-84. PubMed PMID: 11281504.

32: Shudo K. [From cancer prevention to cancer treatment]. Yakugaku Zasshi. 2000 Oct;120(10):987-95. Review. Japanese. PubMed PMID: 11082709.

33: Begleiter A. Clinical applications of quinone-containing alkylating agents. Front Biosci. 2000 Nov 1;5:E153-71. Review. PubMed PMID: 11056078.

34: Baba H, Kohnoe S, Endo K, Ikeda Y, Toh Y, Nakashima H, Okamura T. [State of the treatment for gastrointestinal cancer]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1233-46. Review. Japanese. PubMed PMID: 10945022.

35: Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg. 2000 Jun;66(6):561-8. PubMed PMID: 10888132.

36: Shido A, Ohmura S, Yamamoto K, Kobayashi T, Fujimura T, Yonemura Y. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg. 2000 May;24(5):507-11. PubMed PMID: 10787067.

37: Sakurai T, Tanino H, Oura S, Suzuma T, Yamamiti N, Yoshimasu T, Sakurai T, Naito Y. [Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response]. Gan To Kagaku Ryoho. 2000 Mar;27(3):423-7. Japanese. PubMed PMID: 10740636.

38: Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M, Kawabata K, Hayashi H, Shiraishi T, Imai S, Tsuchitani T, Mizuta J, Nakagawa M, Fukumoto M. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer. 1999 May;80(5-6):775-85. PubMed PMID: 10360655; PubMed Central PMCID: PMC2362297.

39: Nagata Y, Okajima K, Kokubo M, Kanamori S, Fujiwara K, Mizowaki T, Sasai K, Hiraoka M, Kataoka N, Konishi I. Clinical results of transcatheter arterial infusion for uterine cervical cancer. Am J Clin Oncol. 1999 Feb;22(1):97-102. PubMed PMID: 10025392.

40: Tomita A, Fuchino Y, Otsuka K, Shinohara T, Tanaka SN, Umeno T, Ikeda S. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res. 1998 Sep-Oct;18(5D):3937-9. PubMed PMID: 9854507.

41: Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res. 1998 May-Jun;18(3C):2203-10. Review. PubMed PMID: 9703784.

42: Marinelli A, Vahrmeijer AL, van de Velde CJ. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res. 1998;147:83-94. Review. PubMed PMID: 9670271.

43: Vahrmeijer AL, Van Der Eb MM, Van Dierendonck JH, Kuppen PJ, Van De Velde CJ. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol. 1998 Apr-May;14(3):262-8. Review. PubMed PMID: 9548610.

44: Masters JR, Know RJ, Hartley JA, Kelland LR, Hendriks HR, Connors T. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum. Biochem Pharmacol. 1997 Feb 7;53(3):279-85. PubMed PMID: 9065731.

45: Takeda S, Ikeba K, Ohokubo T, Sodemoto T, Yamamoto T, Takagi A, Hayashi N, Kinoshita K. [Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy]. Gan To Kagaku Ryoho. 1996 Oct;23(12):1697-703. Japanese. PubMed PMID: 8886048.

46: Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer. 1996 Jun;14(2-3):301-14. PubMed PMID: 8794412.

47: Chung YC, Huang MT, Chang CN, Huang TW. Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis. J Formos Med Assoc. 1996 Feb;95(2):138-43. PubMed PMID: 9064002.

48: Zaniboni A, Meriggi F, Alghisi A, Mutti S, Distefano L, Rizzi A, Bettini L, Simoncini E, Marpicati P, Montini E, et al. Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study. Tumori. 1995 Nov-Dec;81(6):435-7. PubMed PMID: 8804471.

49: Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg. 1995 Jul-Aug;19(4):565-9. PubMed PMID: 7676701.

50: Goseki N, Maruyama M, Nagai K, Kando F, Endo M, Shimoju K, Wada Y. [Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C]. Gan To Kagaku Ryoho. 1995 Jul;22(8):1028-35. Japanese. PubMed PMID: 7611753.

51: Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H, Takiguchi S, Kono A. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anticancer Drugs. 1995 Jun;6(3):413-8. PubMed PMID: 7670139.

52: Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba E, Nakamura M, Niho Y. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res. 1995 Mar-Apr;15(2):405-9. PubMed PMID: 7763013.

53: Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res. 1995 Mar-Apr;15(2):543-50. PubMed PMID: 7539237.

54: Furukawa Y, Otani Y, Ihara A, Tsuji R, Okamura R, Sato K, Hiki Y. [Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer]. Gan To Kagaku Ryoho. 1994 Dec;21 Suppl 4:453-7. Japanese. PubMed PMID: 7802449.

55: Motohara T, Ozawa Z, Morita S. [Intra-arterial chemotherapy for the treatment of advanced hepatocellular carcinoma through implantable port (reservoir)]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2645-8. Japanese. PubMed PMID: 7979426.

56: Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994 Nov;48(5):794-847. Review. PubMed PMID: 7530632.

57: Elliott WL, Roberts BJ, Howard CT, Leopold WR 3rd. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994 Aug 15;54(16):4412-8. PubMed PMID: 8044790.

58: Fujita F, Fujita M, Fujita M, Sakamoto Y. [Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice]. Gan To Kagaku Ryoho. 1994 Aug;21(10):1619-25. Japanese. PubMed PMID: 8060137.

59: Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994 Aug;20(2):295-301. PubMed PMID: 8045490.

60: Kawahara H, Hirai K, Ashikaga K, Yamada Y, Kimura C, Kuroda H, Sato K, Ono M, Aoki T. [The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer]. Gan To Kagaku Ryoho. 1994 Jul;21(8):1215-9. Japanese. PubMed PMID: 8031164.

61: Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg. 1994 Jul;168(1):36-40. PubMed PMID: 8024097.

62: Herman TS, Teicher BA. Summary of studies adding systemic chemotherapy to local hyperthermia and radiation. Int J Hyperthermia. 1994 May-Jun;10(3):443-9. PubMed PMID: 7930812.

63: Marchiori L, Mansueto GC, Nifosi F, Bortolasi L, Dal Dosso I, Facci E, Perus G, Nicoli N. [The treatment of hepatocellular carcinoma by chemoembolization]. Chir Ital. 1994;46(1):17-22. Italian. PubMed PMID: 8025966.

64: Konno T, Kai Y, Yamashita R, Nagamitsu A, Kimura M. Targeted chemotherapy for unresectable primary and metastatic liver cancer. Acta Oncol. 1994;33(2):133-7. PubMed PMID: 7515628.

65: Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, et al. A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res. 1993 Dec 1;53(23):5649-53. PubMed PMID: 8242619.

66: Taguchi T, Kondo M, Tanikawa K, Nakamura H, Okawa T, Ogawa N. [Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)]. Gan To Kagaku Ryoho. 1993 Oct;20(13):2027-35. Japanese. PubMed PMID: 8215477.

67: Taguchi T, Tanikawa K, Sano K, Nakamura H, Okawa T, Miura T, Ogawa N. [Multi-center cooperative phase II study of combined infusion of PJ-203 (degradable starch microspheres) into hepatic artery in metastatic liver cancer]. Gan To Kagaku Ryoho. 1993 Oct;20(13):2015-25. Japanese. PubMed PMID: 8215476.

68: Yamauchi M, Kondo T. [Multi-institutional feasibility study of SDI test for its application to the adjuvant chemotherapy of gastric cancer]. Gan To Kagaku Ryoho. 1993 Mar;20(4):432-9. Japanese. PubMed PMID: 8452380.

69: Maehara Y, Takahashi I, Yoshida M, Baba H, Kusumoto H, Anai H, Sugimachi K. Postgastrectomy anticancer chemotherapy for stage IV gastric cancer equally tolerable for patients under and over age 65. Anticancer Res. 1993 Jan-Feb;13(1):27-9. PubMed PMID: 8476223.

70: Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 1992 Mar 14;339(8794):629-31. PubMed PMID: 1347336.

71: Ikeda K, Inoue H, Yano T, Kobayashi H, Nakajo M. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol. 1992;31 Suppl:S65-8. PubMed PMID: 1333910.

72: Tseng CC, Nio Y, Shiraishi T, Tsubono M, Morimoto H, Kawabata K, Masai Y, Tun T, Fukumoto M, Tobe T. Comparative study on various combination chemotherapies against human gastric cancer xenograft lines of well- and poorly-differentiated adenocarcinomas transplanted in nude mice. Anticancer Drugs. 1991 Oct;2(5):457-64. PubMed PMID: 1804388.

73: Ku Y, Saitoh M, Tominaga M, Iwasaki T, Maekawa Y, Shiki H, Saitoh Y. [A new method of intraarterial high dose chemotherapy for unresectable hepatomas using direct hemoperfusion under hepatic venous isolation (HVI.DVP)]. Nippon Geka Gakkai Zasshi. 1991 Sep;92(9):1338-41. Japanese. PubMed PMID: 1658593.

74: Franchi F, Barone C, Seminara P, Codacci-Pisanelli G, Codacci-Pisanelli M, Ferri GM, Garufi C, Grieco A, Pagani V. 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. Med Oncol Tumor Pharmacother. 1991;8(2):75-8. PubMed PMID: 1749303.

75: Sugihara K, Auther C, Mori S, Nishihira T, Matsumoto T, Kawachi S, Ishikawa M, Takahashi M, Nakajima T, Kosaki G, et al. [Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group]. Gan To Kagaku Ryoho. 1990 Dec;17(12):2405-13. Japanese. PubMed PMID: 2124434.

76: Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol. 1990 Aug-Nov;7(1-3):209-22. Review. PubMed PMID: 2081925.

77: Yasumoto R, Asakawa M, Yoshihara H, Sakamoto W, Iseki T, Nakatani T, Wada S, Kishimoto T, Maekawa M, Nishio S, et al. [Intravesical instillation chemotherapy of anticancer agents including cylocide: studies of prophylactic effects on the recurrence]. Hinyokika Kiyo. 1990 Apr;36(4):407-13. Japanese. PubMed PMID: 2116082.

78: Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M, Fueki R. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi. 1989 Dec 20;24(11):2587-93. PubMed PMID: 2559129.

79: Nakazato H, Koike A, Ichihashi H, Saji S, Danno M, Ogawa N. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer]. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 1):2563-76. Japanese. PubMed PMID: 2505682.

80: Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res. 1989 Aug 1;49(15):4098-102. PubMed PMID: 2472873.

81: Kaibara N, Hamazoe R, Iitsuka Y, Maeta M, Koga S. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology. 1989 Apr;36(2):75-8. PubMed PMID: 2499527.

82: Matsumura Y. [Intravesical chemotherapy of superficial bladder tumors]. Gan To Kagaku Ryoho. 1989 Feb;16(2):193-8. Review. Japanese. PubMed PMID: 2645832.

83: Takada M, Fukuoka M, Takifuji N, Sakai N, Ryu S, Masuda N, Matsui K, Negoro S, Kusunoki Y, Tsubura E. [Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method]. Gan To Kagaku Ryoho. 1988 Nov;15(11):3095-101. Japanese. PubMed PMID: 3142367.

84: Nishiyama M, Takagami S, Kirihara Y, Saeki T, Niimi K, Nosoh Y, Hirabayashi N, Niimoto M, Hattori T. The indications of chemosensitivity tests against various anticancer agents. Jpn J Surg. 1988 Nov;18(6):647-52. PubMed PMID: 3073241.

85: Akiyoshi T, Arinaga S, Takamuku K, Wada T, Koba F, Tsuji H. A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma. Jpn J Surg. 1988 Sep;18(5):521-6. PubMed PMID: 3230726.

86: Yamada R, Tsuda M, Sato M, Nakayama T, Nishioka S, Yataka I, Nakamura K, Onoyama Y, Kanno T, Nakatsuka H, et al. [The role of antineoplastic solution in transcatheter hepatic arterial embolization--in terms of survival rates affecting anticancer agents together with gelatin sponge]. Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2621-6. Japanese. PubMed PMID: 2843130.

87: Kim JP. Immunochemosurgery as a new approach to reasonable treatment of advanced cancer. Ann Acad Med Singapore. 1988 Jan;17(1):48-54. PubMed PMID: 3056221.

88: Matsumura K, Sawada K, Fukuma S, Kuwahara T, Maruyama K. [A trial of sustained-release anticancer chemotherapy with silicone]. Gan No Rinsho. 1987 Sep;33(11):1337-42. Japanese. PubMed PMID: 3118076.

89: Kubo O, Himuro H, Inoue N, Tajika Y, Tajika T, Tohyama T, Sakairi M, Yoshida M, Kaetsu I, Kitamura K. [Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. No Shinkei Geka. 1986 Sep;14(10):1189-95. Japanese. PubMed PMID: 3024049.

90: Hagiwara A, Ahn T, Ueda T, Iwamoto A, Ueda T, Torii T, Takahashi T. Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. Anticancer Res. 1986 Sep-Oct;6(5):1005-8. PubMed PMID: 2432828.

91: Tamada R. [Surgery and adjuvant therapy of gastric cancer]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1555-63. Japanese. PubMed PMID: 3089173.

92: Wakui A, Kasai M, Konno K, Abe R, Kanamaru R, Takahashi K, Nakai Y, Yoshida Y, Koie H, Masuda H, et al. [Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):1050-9. Japanese. PubMed PMID: 3083785.

93: Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M. Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects. JAMA. 1981 Mar 20;245(11):1123-7. PubMed PMID: 6162038.

94: Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer. 1981 Mar 15;47(6 Suppl):1724-8. PubMed PMID: 6456058.

95: Salmon SE, Meyskens FL Jr, Alberts DS, Soehnlen B, Young L. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):1-12. PubMed PMID: 7226159.